Leadership Overview
Intas has 10 executives leading key functions including strategy, operational oversight, financial management, and global market expansion.
Focused on advancing pharmaceutical research and manufacturing excellence, Intas delivers high-quality healthcare solutions to global markets while maintaining a commitment to innovation and patient-centric development from its headquarters in India.
Focused on advancing pharmaceutical research and manufacturing excellence, Intas delivers high-quality healthcare solutions to global markets while maintaining a commitment to innovation and patient-centric development from its headquarters in India.
Leadership Roles at Intas
Vibhuti Bhatt - Chief Executive Officer
Vibhuti Bhatt, the Chief Executive Officer at Intas, directs the overarching corporate strategy and long-term vision for the organization. By aligning research initiatives with global pharmaceutical demands, the Chief Executive Officer ensures consistent growth across international markets. This leadership role involves constant collaboration with the board to refine manufacturing processes and enhance product efficacy. Vibhuti Bhatt monitors the competitive landscape to identify emerging opportunities in drug development and therapeutic innovation. Through rigorous oversight of organizational performance, the Chief Executive Officer maintains high standards of operational excellence. The strategic focus remains on scaling production capabilities while upholding the core mission of providing accessible healthcare solutions. By fostering a culture of scientific advancement, the Chief Executive Officer drives the company toward sustained market leadership and improved patient outcomes on a global scale.
Jayesh Shah - Whole-time Director. Chief Financial Officer
Jayesh Shah, the Whole-time Director. Chief Financial Officer at Intas, directs the financial planning, budgeting, and fiscal health of the organization. By managing capital allocation and investment strategies, the Chief Financial Officer ensures that the company maintains the liquidity necessary for research and manufacturing expansion. This role involves overseeing financial reporting and compliance with international accounting standards. Jayesh Shah drives the development of financial models that support long-term growth and risk mitigation. Through the analysis of market performance, the Chief Financial Officer provides critical insights that inform strategic decision-making at the board level. The leadership focus centers on maximizing shareholder value while ensuring the financial sustainability of the company's global operations. By maintaining rigorous financial controls, the Chief Financial Officer supports the overall mission of delivering high-quality pharmaceutical products to the global market.
Abhimanyu Ojha - Global Chief Financial Officer & Global President, Finance
Abhimanyu Ojha, the Global Chief Financial Officer & Global President, Finance at Intas, oversees the global financial strategy and fiscal governance across all international operations. By managing currency risk and international tax planning, the Global Chief Financial Officer & Global President, Finance ensures the stability of the company's global financial structure. This role involves coordinating with regional finance teams to maintain consistent reporting and operational efficiency. Abhimanyu Ojha drives the strategic investment in global infrastructure to support the company's expansion into new territories. Through the oversight of financial performance, the Global Chief Financial Officer & Global President, Finance provides the data-driven foundation for strategic growth initiatives. The leadership focus centers on optimizing the global balance sheet and ensuring that financial resources are directed toward high-growth opportunities. By maintaining fiscal discipline, the Global Chief Financial Officer & Global President, Finance supports the company's long-term success.
Kirti Maheshwari - Chief Operating Officer
Kirti Maheshwari, the Chief Operating Officer at Intas, manages the daily operational workflows and internal scaling of manufacturing processes. By optimizing production efficiency, the Chief Operating Officer ensures that the company meets high-volume demands without compromising quality. This role involves overseeing the integration of automated systems across various manufacturing sites to reduce operational costs. Kirti Maheshwari coordinates with department heads to streamline cross-functional communication and project execution. Through the implementation of lean manufacturing principles, the Chief Operating Officer drives improvements in resource utilization and waste reduction. The leadership focus remains on maintaining a stable and scalable operational environment that supports the company's global growth objectives. By monitoring performance metrics, the Chief Operating Officer ensures that all internal processes align with the broader strategic goals of the organization and its commitment to pharmaceutical excellence.
Vijay Teng - Global President, Animal Health & Fertility
Vijay Teng, the Global President, Animal Health & Fertility at Intas, directs the development and commercialization of specialized pharmaceutical products for animal health and fertility markets. By overseeing the research and manufacturing of these niche products, the Global President, Animal Health & Fertility ensures that the company meets the specific needs of veterinary and reproductive healthcare sectors. This role involves managing the global distribution networks for these specialized portfolios. Vijay Teng drives the strategic initiatives that expand the company's presence in the animal health and fertility industries. Through the coordination of clinical research and market outreach, the Global President, Animal Health & Fertility ensures that the company remains a leader in these segments. The leadership focus remains on delivering innovative solutions that improve health outcomes in animal and fertility care. By optimizing product performance, the Global President, Animal Health & Fertility supports the company's overall growth.
Avinash Joshi - President, Quality
Avinash Joshi, the President, Quality at Intas, directs the global quality assurance and regulatory compliance frameworks across all manufacturing facilities. By establishing rigorous quality control protocols, the President, Quality ensures that every pharmaceutical product meets international safety and efficacy standards. This role involves overseeing audits and maintaining compliance with global health authorities. Avinash Joshi drives the implementation of quality management systems that prevent defects and ensure consistency in production. Through the continuous monitoring of manufacturing processes, the President, Quality identifies areas for improvement and risk mitigation. The leadership focus centers on upholding the company's reputation for reliability and safety in the pharmaceutical market. By fostering a culture of quality, the President, Quality ensures that the organization maintains its license to operate in diverse global markets and continues to provide safe healthcare solutions to patients worldwide.
Anshu Verma - Senior General Manager, External Manufacturing (Chief Marketing Officer and CDMO)
Anshu Verma, the Senior General Manager, External Manufacturing (Chief Marketing Officer and CDMO) at Intas, directs the external manufacturing partnerships and global marketing strategies. By managing the contract development and manufacturing organization (CDMO) relationships, the Chief Marketing Officer and CDMO ensures that external production aligns with internal quality standards. This role involves identifying and vetting manufacturing partners to expand the company's production capacity. Anshu Verma drives the marketing initiatives that promote the company's pharmaceutical portfolio to healthcare providers and distributors. Through the coordination of external manufacturing and marketing efforts, the Chief Marketing Officer and CDMO optimizes the supply chain and market reach. The leadership focus remains on building strong alliances that enhance the company's ability to deliver products efficiently. By leveraging external expertise, the Chief Marketing Officer and CDMO supports the company's growth in competitive global markets.
Urmish Chudgar - Managing Director
Urmish Chudgar, the Managing Director at Intas, oversees the strategic expansion of pharmaceutical manufacturing operations. Focusing on the integration of advanced research methodologies, the Managing Director ensures that production facilities meet stringent international quality benchmarks. This role involves coordinating with technical teams to optimize the development of complex drug formulations. Urmish Chudgar drives initiatives that enhance the efficiency of the supply chain, ensuring that life-saving medications reach diverse global markets effectively. By managing capital investments in new technology, the Managing Director supports the company's commitment to innovation. The leadership approach emphasizes sustainable growth and the continuous improvement of pharmaceutical delivery systems. Through careful analysis of market trends, the Managing Director positions the organization to address evolving healthcare needs while maintaining a robust and reliable manufacturing infrastructure.
Nimish Chudgar - Managing Director
Nimish Chudgar, the Managing Director at Intas, manages the commercial strategy and business development efforts across international territories. By identifying key growth regions, the Managing Director facilitates the entry of pharmaceutical products into new markets. This leadership role requires close coordination with regulatory bodies to ensure compliance and market access for diverse therapeutic portfolios. Nimish Chudgar directs the alignment of commercial objectives with the company's research capabilities to maximize market penetration. Through the development of strategic partnerships, the Managing Director strengthens the global footprint of the organization. The focus remains on scaling commercial operations to meet the rising demand for high-quality pharmaceuticals. By optimizing sales and distribution networks, the Managing Director ensures that the company maintains a competitive edge while delivering value to stakeholders and patients worldwide.
Binish Chudgar - Managing Director
Binish Chudgar, the Managing Director at Intas, leads the organizational efforts in research and development to pioneer new pharmaceutical solutions. By overseeing the pipeline of drug discovery, the Managing Director ensures that scientific advancements translate into viable market products. This role involves managing the allocation of resources toward high-impact therapeutic areas and clinical trials. Binish Chudgar drives the collaboration between laboratory teams and manufacturing units to streamline the transition from research to commercial production. Through the implementation of cutting-edge technology, the Managing Director enhances the precision and speed of the development process. The leadership focus centers on maintaining a robust portfolio that addresses unmet medical needs. By fostering innovation, the Managing Director secures the long-term viability of the company's product offerings and reinforces its reputation for excellence in the pharmaceutical industry.
Explore Leadership Teams in Manufacturing
Astellas Pharma is engaged in the manufacturing, marketing, import, and export of pharmaceuticals. It is headquartered in Tokyo, Japan.
Company Leadership RT
MB
KS
AK
Fresenius Kabi, a subsidiary of Fresenius, is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. Fresenius Kabi is headquartered in Bad Homburg, Germany with locations around the world.
Company Leadership MV
SM
CM
RT
Founded in 1974, Accupac is headquartered in Mainland, Pennsylvania. They provide outsourced manufacturing and packaging solutions to pharmaceutical and over-the-counter personal care product manufacturers.
Company Leadership DR
JW
KG
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CC
BS
SR
Frequently Asked Questions Regarding Intas Top Executives and Leadership Team
